Sonoma Biotherapeutics Announces Transition of Jeff Bluestone, PhD, to Advisor; Appoints Stephen Dilly, MBBS, PhD, as President and Chief Executive Officer [Yahoo! Finance]
Codexis, Inc. (CDXS)
Last codexis, inc. earnings: 2/27 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.codexis.com/investors
Company Research
Source: Yahoo! Finance
Dr. Dilly to bring track record in biopharmaceutical leadership, business development and drug development to new leadership role CEO transition to drive next stage of growth following positive first-in-human data from SBT-77-7101 trial SOUTH SAN FRANCISCO, Calif. & SEATTLE, November 17, 2025 BUSINESS WIRE Sonoma Biotherapeutics, Inc. , a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced that its Board of Directors has appointed Stephen Dilly, MBBS, PhD, former President and Chief Executive Officer (CEO) of Codexis, Inc., and current Chair of the Codexis Board, as the Company's new President, CEO and member of the Board of Directors, effective today. The Company also announced that co-founder Jeff Bluestone, PhD, will continue to serve as a member of the Board of Directors and as Advisor to SonomaBio, following his leadership in the Company's founding, development, and growth sin
Show less
Read more
Impact Snapshot
Event Time:
CDXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXS alerts
High impacting Codexis, Inc. news events
Weekly update
A roundup of the hottest topics
CDXS
News
- Codexis' ECO Synthesis® Manufacturing Platform: Transforming RNA Therapeutics [CBS News]CBS News
- Codexis Announces Signing of Lease for GMP Manufacturing Facility [Yahoo! Finance]Yahoo! Finance
- Codexis Announces Signing of Lease for GMP Manufacturing FacilityGlobeNewswire
- Codexis (NASDAQ:CDXS) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CDXS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> MarketBeat
- Codexis Reports Third Quarter 2025 Financial ResultsGlobeNewswire
CDXS
Earnings
- 11/6/25 - Miss
CDXS
Sec Filings
- 12/5/25 - Form SCHEDULE
- 12/1/25 - Form 4
- 11/25/25 - Form 4
- CDXS's page on the SEC website